The Lancet Oncology in conversation with

Neerja Bhatla on a new quadrivalent HPV vaccine

November 29, 2023 The Lancet Group
Neerja Bhatla on a new quadrivalent HPV vaccine
The Lancet Oncology in conversation with
More Info
The Lancet Oncology in conversation with
Neerja Bhatla on a new quadrivalent HPV vaccine
Nov 29, 2023
The Lancet Group

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Show Notes

Professor Neerja Bhatla (All India Institute of Medical Sciences, New Delhi, India) discusses her Article on the Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India.

Read the full article:
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00480-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet & https://Twitter.com/TheLancetOncol
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv